Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Mehr anzeigen
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic...
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.3367003367 | 2.97 | 3.5 | 2.5 | 160162 | 2.89644851 | CS |
| 4 | -3.43 | -53.5101404056 | 6.41 | 10.02 | 2.5 | 1343275 | 3.70253534 | CS |
| 12 | -2.788 | -48.3356449376 | 5.768 | 10.02 | 2.5 | 499958 | 3.94373322 | CS |
| 26 | -10.94 | -78.591954023 | 13.92 | 16 | 2.5 | 296794 | 4.58002434 | CS |
| 52 | -7.74 | -72.2014925373 | 10.72 | 18.7192 | 2.5 | 187048 | 6.60018647 | CS |
| 156 | -1513.8584 | -99.803538729 | 1516.8384 | 1649.4016 | 2.5 | 1912246 | 600.8652315 | CS |
| 260 | -15323.1 | -99.9805560195 | 15326.08 | 39916.8 | 2.5 | 2320942 | 2601.90000055 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
